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ABSTRACT 
Aim: The pathology of heart failure is characterized by poorly contracting and dilated ventricles. 
At the cellular level, this is associated with lengthening of individual cardiomyocytes and loss of 
sarcomeres. While it is known that the transcription factor myocyte enhancer factor -2 (MEF2) is 
involved in this cardiomyocyte remodeling, the underlying mechanism remains to be elucidated. 
Here, we aim to mechanistically link MEF2 target genes with loss of sarcomeres during 
cardiomyocyte remodeling.  
Methods and Results: Neonatal rat cardiomyocytes overexpressing MEF2 elongated and lost 
their sarcomeric structure. We identified myotonic dystrophy protein kinase (DMPK) as direct 
MEF2 target gene involved in this process. Adenoviral overexpression of DMPK E, the isoform 
upregulated in heart failure, resulted in severe loss of sarcomeres in vitro and transgenic mice 
overexpressing DMPK E displayed disruption of sarcomere structure and cardiomyopathy in 
vivo. Moreover, we found a decreased expression of sarcomeric genes following DMPK E gain-
of-function. These genes are targets of the transcription factor serum response factor (SRF) and 
we found that DMPK E acts as inhibitor of SRF transcriptional activity.  
Conclusions: Our data indicate that MEF2-induced loss of sarcomeres is mediated by DMPK 
via a decrease in sarcomeric gene expression by interfering with SRF transcriptional activity. 
Together, these results demonstrate an unexpected role for DMPK as a direct mediator of 
adverse cardiomyocyte remodeling and heart failure. 
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INTRODUCTION 
 
The heart responds to stress or injury by hypertrophic growth, an initially compensatory 
structural remodeling, which often progresses to cardiac wall thinning, chamber dilation and 
heart failure. Although this transition from cardiac hypertrophy to heart failure has been 
associated with lengthening of individual cardiomyocytes and loss of sarcomeres1-3, the 
mechanisms underlying these changes in cardiomyocyte structure remain to be elucidated. 
Increasing evidence, however, suggests a role for the transcription factor myocyte enhancer 
factor-2 (MEF2) as trigger for this adverse structural remodeling of cardiomyocytes4, 5.  
 MEF2 was originally identified as a muscle-specific DNA binding factor that recognizes 
conserved A/T-rich elements in enhancers of numerous muscle-specific genes6. To date, four 
MEF2 genes, mef2a, -b, -c, and -d, have been characterized in vertebrates, with an expression 
pattern and function that extends beyond striated muscle. MEF2 transcription factors share high 
homology in an amino-terminal MADS (MCM1, Agamous, Deficiens, and Serum response 
factor) box and an adjacent MEF2-specific domain, which together mediate dimerization and 
binding to the consensus DNA sequence CTA(A/T)4TA(G/A)7, 8. MEF2 has been implicated in 
the embryonic development of cardiac, skeletal, and smooth muscle, and in postnatal heart 
disease9. 
 MEF2 has initially been postulated to play a role in the development of cardiac 
hypertrophy, as its activity is upregulated by several pro-hypertrophic signaling cascades, 
including calcineurin, calcium/calmodulin-dependent protein kinase, and mitogen-activated 
protein kinase pathways10. We and others, however, have demonstrated that overexpression of 
either MEF2A, MEF2C or MEF2D in the postnatal heart minimally triggers the classical 
hypertrophic growth response, but rather induces dilated cardiomyopathy4, 5, 11. At the cellular 
level, MEF2 activation resulted in elongation of cardiomyocytes and possibly disorganization of 
sarcomere structure4, 5. Conversely, in vivo inhibition of MEF2 activity did not prevent 
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calcineurin-induced cardiac hypertrophy, but profoundly reduced cardiac dilation and improved 
contractility4. Furthermore, cardiac specific deletion of MEF2D protected against pressure 
overload-induced cardiac remodeling and dysfunction11. Overall, these results imply that MEF2 
activates a gene program triggering cardiac dilation and loss of contractility. However, the 
therapeutic value of targeting MEF2 to prevent cardiac dilation and dysfunction in heart failure 
has been challenged, since inhibition of all MEF2 activity leads to mitochondrial dysfunction 
accelerating heart failure development12. 
 Since previous results indicate that MEF2 regulates expression of genes controlling both 
the adaptive response of the heart to stress as well as genes involved in the maladaptive 
structural remodeling during heart failure development, we aimed to identify MEF2 target genes 
responsible for the adverse cardiomyocyte remodeling associated with cardiomyopathy. Here, 
we describe myotonic dystrophy protein kinase (DMPK) as transcriptional target of MEF2 
involved in loss of sarcomere structure in heart failure. 
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METHODS 
Detailed experimental protocols are in the Supplementary material online. 
 
Recombinant viruses. Recombinant adenoviruses were generated as described previously4. 
Lentiviruses were generated by cloning cDNA inserts into pLenti-C-GFP (Origine, PS100065) or 
pLenti-C-tRFP (Origine, PS100074) and co-transfection with third-generation lentiviral packaging 
plasmids pMDLg/pRRE (Addgene, 12251), pRSV-Rev (Addgene, 12253) and the pMD2.G 
envelope plasmid (Addgene, 12259) into HEK293T cells. 
 
Cell culture and transient transfection assays. Neonatal rat ventricular cardiomyocytes 
(NRCM) were isolated from 1-3 days old Wistar rats and cultured as described before4. Low 
passage HEK293T cells were cultured in DMEM supplemented with 10% FBS. NkL-TAg cells 
were cultured as described previously13. NkL-TAg cells were transiently transfected using 
FuGENE 6 reagent (Roche). NRCM were transfected using Lipofectamin 2000 (Invitrogen). 
 
Generation of stable cardiac cell lines. Two independent double stable NkL-TAg cell lines 
(TR1-194 and TR4-39), inducibly expressing the constitutively active MEF2VP16 (caMEF2), 
were generated using the T-REX system (Invitrogen). 
 
Gene expression profiling. TR1-194 and TR4-39 clones were maintained in parallel cultures, 
mortalized by overnight AdCre infection, cultured for an additional 3 days in serum-free media 
either in the presence or absence of 24 h Dox-treatment. Three corresponding cultures were 
pooled, total RNA extracted using TRIzol (Invitrogen) and cleaned with Qiagen RNeasy Mini Kits 
(Qiagen). RNA quantity was measured with a NanoDrop® ND-1000 UV-Vis Spectrophotometer 
(Wilmington), and RNA quality was monitored using an Agilent 2100 bioanalyzer. Gene 
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expression profiling was performed using Agilent 44k mouse whole genome microarray slides 
following the manufacturer’s protocol. 
 
Immunofluorescence and confocal microscopy. Cultured cardiomyocytes were fixed for 10 
min in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS for 5 minutes. 
Primary and secondary antibodies were diluted using 1% BSA in TBS and incubations were 
carried out at room temperature for 1 hour. Cells were washed 3 times with PBS for 5 minutes, 
mounted with coverslips in 0.1 M Tris-HCl (pH 9.5)-glycerol (3:7) including 50 mg/ml n-
propylgallate as anti-fading reagent, and analyzed by confocal microscopy using a Zeiss LSM 
510 META instrument or a Leica TCS SP8 X / DMI6000 inverted confocal microscope. 
 
Histology. Hearts were fixed in 4% paraformaldehyde, dehydrated in graded alcohol solutions 
and Histo-Clear and embedded in paraffin. Sections were stained with hematoxylin and eosin 
(H&E), or picrosirius red to determine the amount of fibrosis. For immunofluorescence, primary 
antibodies against α-actinin (A7811, Sigma, 1:500) and SRF (sc-335, Santa Cruz, 1:250) were 
used. 
 
Electron microscopy. Left ventricular tissue was prefixed in 1% glutaraldehyde, 4% 
paraformaldehyde in 0.1 M sodium cacodylate (Merck) and processed for electron microscopy. 
Images were acquired with a FEI technai 12 transmission electron microscope. 
 
Western blot analysis. Protein lysates from cells or cardiac tissue were separated by 
electrophoresis, transferred to polyvinylidene difluoride membranes and processed for 
chemiluminescent detection. Chemiluminescence was captured by the ImageQuant LAS-4000. 
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Reverse-transcription and Real-Time Polymerase Chain Reaction. Total RNA was isolated 
from the indicated cell types or tissue using TRIzol reagent (Invitrogen). One μg of RNA isolated 
from flash-frozen apex was reverse-transcribed using Oligo(dT) primers and Superscript II 
reverse transcriptase (Invitrogen). PCR amplification was performed in a total reaction volume of 
50 μl and PCR products were resolved by agarose gel electrophoresis. Real-time PCR was 
performed in 384-well plates using SYBR Green I master solution (Roche) and the LightCycler 
480 (Roche). 
 
Chromatin immunoprecipitation. Chromatin immunoprecipitation was carried out using the 
Upstate Biotechnology ChIP assay kit. 
 
Animal studies. Cardiac specific DMPK E and DMPK E (K100A) overexpression mice were 
generated by subcloning DMPK E and DMPK E (K100A) cDNA into an αMHC transgenic vector. 
The transgenic vectors were injected into the pronuclei of fertilized FVB oocytes, which were 
transferred to pseudopregnant recipients. Transverse Aortic Constriction (TAC) and 
echocardiography were performed as described previously12. For echocardiography 
measurement, mice were anesthetized using 1.5% isoflurane mixed with 95% O2. For TAC 
surgeries, 8 weeks old male C57/BL6 mice (Harlan) were anesthetized with 2% isoflurane and 
sacrificed 12 weeks after surgery by cervical dislocation in 2% isoflurane. Animal studies 
conformed to the Directive 2010/63/EU of the European Parliament, and were approved by the 
Animal Experimental Committee of the Academic Medical Center, University of Amsterdam. 
 
Statistics. The results are presented as means ± SEM. Statistical analyses were performed 
using INSTAT 3.0 and GraphPad Prism7 software (GraphPad, San Diego) and an unpaired 2-
tailed Student’s t-test, or one way ANOVA followed by Tukey’s post-test. Statistical significance 
was accepted at a P value < 0.05. 
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RESULTS 
 
Activation of MEF2 leads to elongation and loss of sarcomeres in cultured 
cardiomyocytes 
To address the role of MEF2 in structural remodeling of cardiomyocytes, we generated 
adenoviruses expressing either MEF2A (AdMEF2A) or the constitutively active MEF2VP16 
(AdcaMEF2). Isolated neonatal rat cardiomyocytes (NRCM) were infected with AdMEF2A, 
AdcaMEF2 and control AdGFP for 48 hours, fixed and stained for the sarcomeric proteins titin, 
at both the M-band (titin M8) and Z-disc (titin T12), α-actinin (Z-disk) and myomesin (M-band), 
(Fig. 1A and B). First, we determined the ratio of the length of the major and minor axis of cells, 
as a measure of cellular elongation. AdGFP infected cardiomyocytes had a ratio of 2.57 ± 0.16, 
while AdMEF2A and AdcaMEF2 infected cells displayed a 2- and 3 fold increase in major to 
minor axis ratios (5.20 ± 0.50 and 7.70 ± 0.77, respectively; P<0.05) compared to AdGFP-
infected cells (Fig. 1C). Next, we analyzed the MEF2-induced sarcomere phenotype. Non-
infected and AdGFP infected NRCM displayed a regular pattern of sarcomere staining, with a 
regular spacing between the M-band and the Z-disc. In contrast, quantification of myofibrillar 
structure score showed a dramatic loss of sarcomeres in AdMEF2A and AdcaMEF2 infected 
NRCM (Fig. 1D). Combined, these data demonstrate that MEF2 transcriptional activity in 
cultured cardiomyocytes promotes elongation of cardiomyocytes, accompanied by loss of 
sarcomere structure. 
 
MEF2 activates cardiac genes involved in cardiomyocyte structure 
To reveal the potential mechanisms underlying the structural cardiomyocyte changes induced by 
MEF2 transcriptional activity, we screened for MEF2 target genes. For this, we generated a 
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cellular system to inducibly activate MEF2 in NkL-TAg cells, a previously described ventricular 
muscle cell line13 (Fig. S1 and Fig. 2A). We obtained 8 double-stable cell lines, which only 
expressed caMEF2 after doxycyclin (Dox) stimulation, as demonstrated by Western blotting 
using an antibody against VP16 (Fig. S1B) and by immunofluorescent staining (Fig. S1C). To 
control for cell-based variations, we selected 2 TR-caMEF2 clones (TR1-194 and TR4-39) for 
further analysis. Both clones were transiently transfected with 3xMEF2 luc, mortalized with 
AdCre infection13, cultured for 72 hours in serum free media to allow to adopt a ventricular 
muscle cell fate, and exposed to Dox for varying periods to establish at which time-course 
elevated MEF2 transcriptional activity was evident. In both clones, an approximate 5-fold 
increase of MEF2 transcriptional activity was evident at 8 h, compared to TR1-194 and TR4-39 
clones cultured in the absence of Dox (Fig. 2B). After 24 h Dox exposure, both clones 
demonstrated an approximate 10-fold increase in MEF2 transcriptional activity (Fig. 2B). Both 
TR1-194 and TR4-39 cell lines elongated after Cre-induced mortalization and Dox stimulation 
(Fig. S1C). So, we established a novel system that allows inducible activation of MEF2 
transcriptional activity in ventricular muscle cells by addition of doxycyclin to the culture medium. 
 Both inducible caMEF2 ventricular myocyte cell lines were used for a genome-wide 
microarray analysis to identify the earliest gene pattern regulated by MEF2. After cells were 
mortalized by AdCre infection13, cultured in serum free medium for 72 hours and cultured for an 
additional 24 hours in the absence or presence of Dox, we found 75 genes to be differentially 
expressed in both TR1-194 and TR4-39 cells with a fold change in expression ≥2 (P<0.01) after 
Dox stimulation (Supplemental table). Gene ontology classifications revealed an 
overrepresentation of genes in several subclasses, among which cell-matrix adhesion and 
cytoskeletal remodeling (Fig. 2C). Another gene class differentially regulated by MEF2 included 
genes involved in energy metabolism and mitochondrial energy production (Fig. 2C), which is in 
line with previous reports indicating a direct or indirect role for MEF2 to control cardiac energy 
production12, 14, 15. We picked 10 genes and verified differential expression by RT-PCR (Fig. 2D) 
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and QPCR analysis (Fig. 2E). For example, transcripts for integrin alpha-7 (Itga7), nexilin 
(Nexn), connective tissue growth factor (Ctgf), regulatory myosin light chain 9 (Myl9), myotonic 
dystrophy protein kinase (Dmpk), sarcoglycan alpha (Sgca) and sarcoglycan beta (Sgcb) were 
upregulated upon caMEF2 expression in TR1-194 and TR4-39 clones (Fig. 2D and E). In 
contrast, transcripts for integrin beta 4 (Itgb4), glutathione S-transferase alpha 1 (Gsta1) and 
mucin 5 (Muc5b) were downregulated. Combined, these data demonstrate that MEF2 activates 
subsets of genes primarily involved in cardiomyocyte structure and energy metabolism. 
 
DMPK is a MEF2 target gene required for loss of sarcomere structure 
Of all genes found to be upregulated by MEF2 activation, DMPK was of specific interest. DMPK 
is a kinase related to the Rho family of kinases and has been implicated in disruption of 
sarcomere structure in earlier in vitro studies16, 17. Also, DMPK protein levels are increased in 
human failing hearts18. To verify that DMPK represents a direct transcriptional target of MEF2, 
rat, mouse and human orthologs were aligned and analyzed for conserved MEF2 binding sites. 
One conserved MEF2 binding sequence (CTAAATTTAA) was detected 513 bp upstream of the 
transcriptional start site of the rat Dmpk gene (Fig. 3A). We performed ChIP analysis to 
determine whether MEF2 binds to this A/T rich motif (Fig. 3B). Chromatin was 
immunoprecipitated from rat neonatal cardiomyocytes infected with either AdGFP or AdMEF2A, 
using antibodies directed against MEF2 and acetylated histone H3. No antibody 
immunoprecipitates were used as negative control. PCR amplification of the immunoprecipitated 
material using primers flanking the MEF2 site, demonstrated MEF2 binding to the Dmpk 
promoter in cardiomyocytes infected with the MEF2A expressing adenovirus (Fig. 3B). 
 In order to assess the potential role of DMPK in MEF2-induced cardiomyocyte 
remodeling, we evaluated the effect of DMPK siRNA-mediated knockdown during this 
remodeling process. As determined by Western blotting, we established significant knockdown 
of DMPK expression levels by transfecting cardiomyocytes with siRNAs directed against DMPK 
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(Fig. 3C). Infection with AdMEF2A and especially AdcaMEF2 enhanced DMPK protein levels in 
cardiomyocytes pre-transfected with control siRNA. This increase in expression, however, was 
inhibited in cardiomyocytes pre-transfected with siRNA targeting DMPK (Fig. 3C). Next, we 
investigated the effect of DMPK inhibition on MEF2-induced structural remodeling of 
cardiomyocytes. Pre-transfection with control siRNA had no effect on cellular morphology. MEF2 
activation induced elongation and loss of sarcomere structure in cardiomyocytes transfected with 
control siRNA (Fig. 3D). Cardiomyocytes pre-transfected with DMPK siRNA, however, showed a 
clear attenuation of characteristic MEF2-induced sarcomeric degeneration (Fig. 3D). 
Conclusively, DMPK is a direct cardiac MEF2 target gene and promotes loss of sarcomere 
structure. 
 
DMPK E is increased in heart failure and is sufficient to induce loss of sarcomere 
structure 
To assess a possible role for DMPK in loss of sarcomere structure in the intact heart, we 
analyzed DMPK protein and mRNA levels in hearts from mice subjected to transverse aortic 
constriction (TAC) or sham surgery (Fig. S3). Western blot analysis displayed a significant 
increase in DMPK protein levels only in failing mouse hearts (ejection fraction (EF) <35%) and 
not in hearts from mice with cardiac hypertrophy and preserved cardiac function (Fig. 4A and B). 
DMPK RNA is subject to extensive alternative splicing, giving rise to 6 major (DMPK A-F) and 
several minor DMPK isoforms19. Alternative splicing events in the C-terminus (mainly resulting in 
in- or exclusion of exons 13 and 14) are likely to be the main determinants of DMPK functional 
variability, since they give rise to DMPK isoforms with long C-termini (DMPK A-D) that can 
anchor into membranes of mitochondria or the sarcoplasmic reticulum, or to smaller isoforms 
(DMPK E and F) with a cytosolic localization due to lack of the C-terminal extension20. So, we 
first determined the expression levels of different DMPK isoforms in failing mouse hearts and 
sham control hearts by RT-PCR using primers spanning exons 13 and 14 (Fig. 4C). 
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Interestingly, mainly the DMPK E isoform, resulting from skipping of both exon 13 and 14, was 
upregulated in failing hearts. Indeed, quantitative PCR (QPCR) specifically for this isoform 
showed a significant increase in DMPK E mRNA in failing hearts (Fig. 4D). Interestingly, RT-
PCR and QPCR analysis in NRCM showed that it is particularly the DMPK E isoform that is 
upregulated upon MEF2 activation (Fig. S3A-C). Western blot analysis demonstrates that both 
the MEF2A and the caMEF2 construct increase DMPK protein levels (Fig. S3D).  
 To further identify a role for DMPK E in sarcomere degeneration, we generated 
adenoviruses expressing either DMPK E (AdDMPK E) or a kinase dead mutant DMPK E 
(AdDMPK E (K100A); Fig. 4E)20 and used these viruses, along with a GFP control virus, to infect 
isolated cardiomyocytes. Immunostaining for α-actinin and quantification of myofibrillar structure 
scores demonstrated a clear loss of sarcomere structure in NRCM 48 hours after infection with 
AdDMPK E, but not with AdDMPK E (K100A) or AdGFP (Fig. 4F and G). Overall, these data 
demonstrate that expression of DMPK E is increased in failing hearts and that overexpression of 
this specific isoform is sufficient to induce loss of sarcomeres in isolated cardiomyocytes. 
Furthermore, the DMPK E-induced effect on sarcomere structure requires DMPK E to be 
enzymatically active, indicating the involvement of one or more downstream phosphorylation 
events. 
 
DMPK E inhibits SRF transcriptional activity 
Loss of sarcomeres can be induced by both an increase in sarcomere protein degradation and a 
decrease in sarcomere generation. To test this, we performed QPCR analysis for several 
sarcomeric genes, including α-actinin (Actn2), titin (Ttn), synaptopodin 2-like (Chapb), skeletal 
alpha actin (Acta1) and myosin light chain 2 (Myl2) on RNA isolated from NRCM infected with 
AdGFP, AdDMPK E, AdDMPK E (K100A) and AdcaMEF2 (Fig. 5A). Strikingly, the expression of 
all sarcomeric genes tested was dramatically reduced in NRCM infected with AdDMPK E 
compared to cells infected with AdGFP or AdDMPK E (K100A). A smaller, but still significant, 
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
CVR-2017-901-R1 
 
13 
 
decrease in Actn2, Ttn, Acta1 and Myl2 mRNA was also observed in NRCM infected with MEF2 
virus, which is in line with DMPK being the MEF2 target involved in sarcomere loss (Fig. 3D). 
The expression level of cardiac NK2 homeobox 5 (Nkx2.5) was similar in all conditions (Fig. 5A), 
assuring an equal number of cardiomyocytes after infection with the different viruses. So, DMPK 
E-induced loss of sarcomeres is caused by a decrease in transcription of sarcomeric genes. 
 Interestingly, among the few known phosphorylation targets of DMPK is serum response 
factor (SRF), a transcription factor controlling cardiac sarcomere gene expression21. To check 
whether DMPK E inhibits SRF transcriptional activity in our cardiomyocytes, we transfected 
NRCM with the SM22 luc reporter for SRF activity together with or without the SRF cofactor 
myocardin (Myocd)22. At baseline, luciferase signal in AdDMPK E infected NRCM was 
significantly lower than in AdGFP or AdDMPK E (K100A) infected cells. Furthermore, co-
transfection with Myocd resulted in a significant increase in luciferase signal, indicating 
enhanced SRF activity, in cells infected with AdGFP and AdDMPK E (K100A), but not in cells 
infected with AdDMPK E (Fig. 5B). These data demonstrate that DMPK E inhibits SRF 
transcriptional activity. 
 DMPK is known to phosphorylate threonine 159 and possibly serine 162 in the MADS 
box, the DNA binding domain of SRF21. These phosphorylation events have been described to 
weaken the binding of SRF to the promoter regions of sarcomeric genes, thereby decreasing 
their expression levels23, 24. Therefore, we explored the potential effects of DMPK E on cellular 
localization of SRF by immunostainings (Fig. 5C and D). NRCM infected with AdGFP or 
AdDMPK E (K100A) displayed an expected nuclear localization of SRF. In contrast, AdDMPK E 
infected NRCM showed a significant increase in translocation of SRF from the nucleus (Fig. 5C 
and D). Next, we compared the effect of the full-length DMPK A isoform and the cytosolic DMPK 
E isoform on both sarcomere disruption and SRF translocation in NRCM (Fig. S4). NRCM 
transduced with DMPK E showed a much larger sarcomere disorganization and more SRF 
translocation than NRCM transduced with DMPK A, indicating that it is the cytosolic variant of 
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DMPK that induces SRF translocation and thereby sarcomere disruption. Combined, DMPK E 
decreases transcription of sarcomeric genes, due to an SRF nucleo-cytoplasmic translocation 
event and concomitant inhibition of SRF transcriptional activity. 
 
DMPK E-induced loss of sarcomere structure requires phosphorylation of SRF 
DMPK is known to phosphorylate SRF at threonine 159 and serine 16221. To investigate whether 
phosphorylation of SRF is the main mechanistic driver for DMPK E-induced sarcomere 
degeneration, we generated lentiviruses expressing either wildtype SRF (SRF-WT), a 
nonphosphorylatable mutant SRF in which the serine and threonine sites have been mutated to 
alanine (SRF-TASA), and a phosphomimic mutant in which these sites have been mutated to 
aspartic acid (SRF-TDSD). We then co-infected NRCM with these viruses and with either 
AdGFP or AdDMPK E, and assessed the amount of nuclear SRF (Fig. 6A and B). Quantification 
of the percentage of nuclear SRF showed that the phosphomimic TDSD SRF mutant 
translocates out of the nucleus independent of DMPK E. Furthermore, the SRF-TASA mutant 
remains located in the nucleus even in the presence of DMPK E.  
 Since the unphosphorylatable TASA SRF mutant remains located in the nucleus, we 
investigated the effect of SRF-TASA overexpression on AdDMPK E-induced loss of sarcomeres 
(Fig. 6C). Quantification of the myofibrillar structure showed that NRCM infected with lenti-SRF-
TASA were protected from DMPK E-induced sarcomere disruption (Fig. 6D). Combined, these 
results demonstrate that DMPK E-induced loss of sarcomeres requires phosphorylation of SRF. 
 
DMPK E activity induces loss of cardiac sarcomere structure and cardiomyopathy in mice 
Our in vitro findings indicate that DMPK is required for MEF2-induced sarcomere loss and that 
DMPK E is sufficient to induce loss of sarcomere structure. To define whether DMPK E is also 
sufficient to induce structural remodeling of the heart, we generated mice expressing either 
DMPK E or DMPK E (K100A) under control of the cardiac specific alpha myosin heavy chain 
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promoter. For both constructs we obtained 2 independent transgenic lines, designated DMPK E 
lines 1 and 2 and DMPK E (K100A) lines 1 and 2, with matched levels of overexpression as 
determined by Western blot analysis (Fig. 7A). QPCR analysis indicates that DMPK E mRNA 
levels in DMPK E (K100A) hearts are higher than in the DMPK E mouse lines (Fig. 7B). DMPK E 
mRNA levels in DMPK E line 2 hearts are lower compared to DMPK E line 1 hearts (Fig. 7B). 
So, hearts of control DMPK E (K100A) mice express equal or slightly higher amounts of DMPK 
E protein compared to DMPK E mice. However, DMPK E (K100A) mice lack DMPK kinase 
activity, as depicted by the absence of DMPK autophosphorylation (no higher DMPK protein 
product on Western blot; Fig. 7A). 
 Strikingly, survival rate was significantly reduced in both DMPK E lines, with mortality of 
70% and 20% in 7-month-old DMPK E line 1 and DMPK E line 2 mice, respectively, compared to 
no mortality in wildtype (WT) or both DMPK E (K100A) mouse lines (Fig. 7C). Hearts from 8-
month-old DMPK E (K100A) mice displayed no structural abnormalities compared to age 
matched WT hearts (Fig. 7D). Hearts from DMPK E transgenic mice, however, showed clear 
signs of cardiomyopathy, with dilation of both ventricles and occasional enlargement of atria, at 
an age of 5 and 8 months for lines 1 and 2, respectively (Fig. 7D). Next, we performed 
echocardiographic analysis of WT, DMPK E and DMPK E (K100A) mice to assess cardiac 
dimensions and function over time. Although we did not find any differences in wall thickness or 
ventricular diameter within 6 months of age, DMPK E transgenic mice displayed a clear loss of 
cardiac function compared to WT and DMPK E (K100A) control mice (Fig. S5A). To assess the 
amount of fibrosis, we performed Sirius Red stainings, which showed a significant increase in 
fibrotic cardiac tissue in DMPK E mice (Fig. S5B). To investigate whether the DMPK E 
phenotype could be due to increased cardiomyocyte death, we assessed the extent of 
cardiomyocyte apoptosis by TUNEL staining (Fig. S6). These data demonstrated that there is no 
increase in cardiomyocyte apoptosis in DMPK E transgenic mice. The cardiomyopathic 
phenotype was further illustrated by a significant increase in heart weight-to-tibia length and lung 
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weight-to-tibia length ratios in both 4-5 month-old DMPK E line 1 and 8-10 month-old DMPK E 
line 2 transgenic mice, compared to 8-10 month-old WT mice (Fig. 7E and F). This increase in 
heart and lung weights was not observed in 8-10 month-old DMPK E (K100A) mice (Fig. 7E and 
F). So, an increase in DMPK E kinase activity in postnatal hearts results in cardiomyopathy and 
death. 
 To obtain more mechanistic insight in the DMPK E induced cardiomyopathy, we 
sacrificed mice at 10 weeks of age and performed electron microscopy on cardiac tissue (Fig. 
7G and H and Fig. S5C). Quantification of sarcomere structure score indicated that sarcomere 
structure is severely disrupted in DMPK E transgenic mice (Fig. 7H). Staining of cardiac sections 
for α-actinin further verified a loss of sarcomere structure in DMPK E mice compared to both WT 
and DMPK E (K100A) mice (Fig. 7I). 
 Furthermore, immunostaining for SRF revealed a significant decrease in cardiomyocytes 
with an SRF positive nucleus in DMPK E mice compared to WT and DMPK E (K100A) mice (Fig. 
7I and J). In line, QPCR for SRF-regulated sarcomeric genes revealed a significant decrease of 
Ttn, Actn2 and Myl2 expression in DMPK E mice, compared to both WT and DMPK E (K100A) 
control mice (Fig. 7K). In contrast to our observations in NRCM (Fig. 5A), Acta1 mRNA levels 
were significantly higher in DMPK E hearts (Fig. 7K), which could be due to the reactivation of 
the fetal gene program during cardiac stress. Overall, an increase in DMPK E kinase activity in 
the heart results in cardiomyopathy. This cardiomyopathy is preceded by a loss of sarcomere 
structure and inhibition of SRF transcriptional activity. 
 
 
DISCUSSION 
 
Ultrastructural changes in cardiomyocytes are characteristic features of heart failure 
development and disruption of sarcomeres is found to be an early predictor of prognosis in 
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dilated cardiomyopathy patients25. Previous work has demonstrated the contribution of MEF2 to 
structural remodeling of cardiomyocytes in heart failure progression4, 5, 11, but the underlying 
mechanism and responsible MEF2 transcriptional targets are unknown. In present study, we 
confirmed the importance of MEF2 in adverse cardiomyocyte remodeling, since MEF2 activation 
induced elongation of cardiomyocytes and loss of sarcomere components at both the M-band 
and Z-disc. Concordantly, the classification profile of MEF2 target genes we identified revealed 
an intimate involvement of MEF2 in regulation of cellular structure. 
We identified DMPK as direct transcriptional target of MEF2 with a crucial role in 
disruption of sarcomere structure (Fig. S7). DMPK did not seem to affect cardiomyocyte length, 
indicating that the MEF2-induced cardiomyocyte elongation involves other MEF2 transcriptional 
targets. DMPK protein levels are found to be increased in human failing hearts18, but DMPK is 
mainly known from its implication in myotonic dystrophy 1 (DM1). DM1 is an inherited 
multisystemic neuromuscular disorder and symptoms include progressive muscle weakness and 
wasting, cataracts, gastro-intestinal problems and cardiac abnormalities26. DM1 has been 
associated with expansion of untranslated CTG repeats in the 3’-untranslated region of DMPK, 
which causes accumulation of DMPK mRNA transcripts in the nucleus, resulting in RNA toxicity 
and trans effects altering expression and alternative splicing of numerous other genes27, 28. It is 
unclear, however, whether these trans RNA processing defects are solely responsible for the 
DM1 cardiac pathology, since altered DMPK levels are by itself sufficient to induce cardiac 
defects similar to those observed in DM1 patients29, 30. Nevertheless, most studies on DM1 focus 
on the pathological effects associated with the untranslated CTG expansion, leaving a functional 
role for DMPK largely unexplored. 
Findings in several other studies underline the potential role for DMPK in cardiomyocyte 
remodeling. DMPK is related to the Rho family of protein kinases, which are associated with 
actin cytoskeletal remodeling31. DMPK is also known to interact with Rac-1, and both DMPK and 
Rac-1 are able to phosphorylate and inhibit myosin phosphatase32, 33. Inhibition of myosin 
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phosphatase and associated increase in myosin phosphorylation is important for sarcomere 
organization34. Also, overexpression of DMPK in chick cardiomyocytes leads to disruption of 
sarcomeres16. Finally, Mulders et al. have demonstrated that overexpression of DMPK E, but not 
the longer DMPK C isoform, hampers sarcomere assembly during differentiation of skeletal 
muscle cells17. Their results suggest that the effects of DMPK E on sarcomere structure mainly 
involve a disturbance in sarcomere formation instead of active breakdown of sarcomere 
components, which is in agreement with our findings that DMPK E inhibits sarcomeric gene 
expression. A recent report by Carell et al.35 suggests that targeting all DMPK isoforms in mice is 
not sufficient to prevent loss of cardiac function after induction of pressure overload. In their 
study, however, they only investigated the effect of DMPK inhibition during early cardiac 
remodeling and not in end-stage heart failure, when DMPK E is upregulated and a disturbance 
in sarcomere formation is expected. 
 The absence of any morphological or functional changes after overexpression of the 
kinase dead DMPK mutant in both our in vitro and in vivo experiments indicates the requirement 
of DMPK enzymatic activity and one or more downstream phosphorylation targets in the cellular 
remodeling process. Besides myosin phosphatase, DMPK is known to phosphorylate a small set 
of other targets, including phospholamban36, phospholemman37, CUG-binding protein38 and 
SRF21. Like MEF2, SRF is a MADS box containing transcription factor essential for cardiac 
differentiation. SRF binds to a DNA consensus element known as CArG box, which is primarily 
found in promoters of genes involved in cell growth, cell movement and contractility24. The 
importance of SRF in the heart is illustrated by several studies in mouse models, which 
demonstrate that SRF loss of function results in dilated cardiomyopathy and death associated 
with decreased levels of sarcomeric proteins9. 
 DMPK has been found to phosphorylate SRF at serines 159 and 162 in the DNA binding 
MADS box domain21. This phosphorylation event has initially been described to activate 
transcription of skeletal alpha-actin21. Later, however, phosphorylation of serine 162 was 
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described to prevent SRF binding to CArG boxes in DNA, allowing this phosphorylation event to 
act as a switch between myogenic and proliferation gene programs23. Our findings are in 
agreement with loss of SRF-DNA binding, since we observed a reduction in SRF transcriptional 
activity in association with translocation of SRF out of the nucleus. A redistribution of SRF from 
the nucleus to the cytosol has been described earlier as mechanism to inhibit SRF 
transcriptional regulation of contractile genes in serum deprived smooth muscle cells39. 
Interestingly, this translocation of SRF was controlled by the Rho kinase pathway40. Cytoplasmic 
accumulation of SRF has also been observed in NRCM after mechanical arrest41.  
In conclusion, our findings identify DMPK as a direct transcriptional target of MEF2, 
promoting sarcomere degeneration, a main characteristic of cardiomyocytes during heart failure 
progression. The loss of sarcomere structure is caused by a reduction of sarcomeric gene 
transcription, which is, at least in part, due to inhibition of SRF transcriptional activity. 
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FIGURE LEGENDS 
 
Figure 1. MEF2 activation induces cardiomyocyte elongation and loss of sarcomeres. 
A. Confocal immunocytochemistry of NRCM after adenoviral overexpression of either GFP, 
MEF2A or constitutively active MEF2 (caMEF2) using antibodies raised against titin epitopes 
located in the Z-disc (titin T12) and in the M-band (titin M8). Scale bar = 10 μm. B. Confocal 
immunocytochemistry of NRCM after adenoviral overexpression of either GFP, MEF2A or 
caMEF2 using anti-sarcomeric α-actinin (Z-disc) and anti-myomesin (M-band). Scale bar = 10 
μm. C. Quantitative examination of cell-length/cell-width ratios of cardiomyocytes from 3 
independent isolations infected with AdGFP (n=102 cells), AdMEF2A (n=101 cells) and 
AdcaMEF2 (n=100 cells). ***P<0.001 versus AdGFP, ##P<0.05 versus AdMEF2A, one way 
ANOVA followed by Tukey’s post-test. D. Quantification of the myofibrillar structure in NRCM 
from 4 independent isolations transduced with either AdGFP (n=190 cells), AdMEF2A (n=280 
cells), or AdcaMEF2 (n=192 cells). ***P<0.001 versus AdGFP, #P<0.05 versus AdMEF2A, one 
way ANOVA followed by Tukey’s post-test. 
 
Figure 2. Characterization of MEF2 target genes in cardiac cell lines inducibly expressing 
caMEF2. 
A. Schematic representation of a double-stable cardiomyocyte cell line harboring a construct 
expressing Tet repressor (TR) and a construct harboring caMEF2 downstream of Tet operators 
(tetO), which expresses caMEF2 only after doxycycline (Dox) stimulation. B. Luciferase 
measurements on TR1-194 and TR4-39 cells, transiently transfected with a MEF2 luciferase 
reporter, indicating an increase in MEF2 activity after Dox stimulation. n=3 replicates. C. Bar 
graph indicating the number of genes identified by microarray analysis to be differentially 
expressed in both TR1-194 and TR4-39 cells in different functional classifications. D. RT-PCR 
validation of mRNA levels of indicated genes in TR1-194 and TR4-39 cells in absence or 
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presence of Dox. Ribosomal protein L7 mRNA levels were determined as control for equal 
loading and amplification. E. QPCR analysis of indicated genes in TR4-39 cells in absence or 
presence of Dox. n=4 replicates. *P<0.05, **P<0.01 and ***P<0.001 versus -Dox. One way 
ANOVA followed by Tukey’s post-test. 
 
Figure 3. DMPK is a transcriptional target of MEF2 promoting sarcomere degeneration. 
A. Sequence alignment of rat, mouse, and human dmpk promoter regions. The gray box 
indicates a conserved MEF2 binding site. B. Chromatin immunoprecipitation (ChIP) analysis 
performed by PCR using primers flanking the MEF2 site on DNA immunoprecipitated using 
either a MEF2 or an acetylated histone H3 antibody. Non-immunoprecipitated DNA was used as 
input control. C. Western blot analysis for DMPK expression in NRCM pre-transfected with 
control or DMPK specific siRNAs and infected with indicated adenoviruses. Immunoreactivity for 
GAPDH serves as protein loading control. D. Confocal immunocytochemistry of NRCM, using an 
α-actinin antibody, demonstrates that knockdown of DMPK attenuates MEF2 induced sarcomere 
degeneration. Experiment has been repeated 3 times and representative images are shown. 
Scale bar = 20 μm. 
 
Figure 4. Expression of DMPK E is increased in failing mouse hearts and is sufficient to 
disrupt sarcomeric organization. 
A. Western blot analysis for DMPK expression in control, failing and hypertrophic mouse hearts 
after TAC, displaying increased DMPK expression only in failing hearts. B. Quantification of 
DMPK protein expression in 6 sham, 4 failing and 4 hypertrophied mice, demonstrating a 
significant increase of DMPK expression in failing, but not hypertrophic mouse hearts. * P<0.05 
vs. sham, one way ANOVA followed by Tukey’s post-test. C. RT-PCR analysis for different 
DMPK splice variants in healthy and failing hearts from mice subjected to sham or TAC surgery. 
Exons 13 and 14 skip is DMPK E. D. QPCR analysis demonstrates a significant increase in 
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expression of the DMPK E isoform in failing mouse hearts. n=9 control mice and 8 heart failure 
mice. *P<0.05, unpaired 2-tailed Student’s t-test. E. Western blot analysis demonstrating 
adenoviral expression of DMPK E and a kinase dead mutant DMPK E (K100A). F. Quantification 
of the myofibrillar structure in NRCM from 3 independent isolations transduced with either 
AdGFP (n=66 cells), AdDMPK E (n=62 cells), or AdDMPK E (K100A) (n=69 cells). ***P<0.001 
versus AdGFP, ###P<0.001 versus AdDMPK E, one way ANOVA followed by Tukey’s post-test. 
G. Representative confocal images of NRCM transduced with AdGFP, AdDMPK E, or AdDMPK 
E (K100A). Scale bar = 20 μm. 
 
Figure 5. DMPK E decreases expression of sarcomeric genes and inhibits SRF 
transcriptional activity. 
A. QPCR analysis indicates a decrease in mRNA levels of sarcomeric genes after DMPK E 
overexpression in NRCM. n=3. *P<0.05, ***P<0.001 versus AdGFP, one way ANOVA followed 
by Tukey’s post-test. B. Luciferase experiment using SM22-luc reporter in NRCM indicates that 
DMPK E inhibits SRF transcriptional activity. n=4 replicates. *P<0.05, ***P<0.001 versus 
AdGFP, one way ANOVA followed by Tukey’s post-test. C and D. Confocal 
immunocytochemistry on NRCM for α-actinin and SRF displays translocation of SRF out of the 
nucleus in cardiomyocytes expressing DMPK E (D). Quantification of the ratio of nuclear versus 
cytoplasmic SRF in NRCM transduced with AdGFP, AdDMPK E and AdDMPK E (K100A) 
showing less nuclear SRF in cells overexpressing DMPK E (C). AdGFP: n=54 cells,  AdDMPK 
E: n=56 cells, AdDMPK E (K100A): n=51 cells from 3 independent cell isolations. ***P<0.001 
versus AdGFP, ###P<0.001 versus AdDMPK E, one way ANOVA followed by Tukey’s post-test. 
Scale bar = 20 μm. 
 
Figure 6. DMPK E-induced loss of sarcomere structure requires phosphorylation of SRF.  
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A. Confocal immunocytochemistry on NRCM co-transduced with either AdGFP or AdDMPK E, 
and lenti-SRF-WT (wildtype SRF), lenti-SRF-TASA (unphosphorylatable mutant) or lenti-SRF-
TDSD (phosphomimic), where the three SRF constructs are tagged with a red fluorescent 
protein (RFP). B. Quantification of the nuclear localization of SRF-WT, SRF-TASA and SRF-
TDSD in NRCM transduced with AdGFP or AdDMPK E. n=33 cells from 3 independent cell 
isolations. ***P<0.001, ###P<0.001 versus corresponding WT, one way ANOVA followed by 
Tukey’s post-test. C. Confocal immunocytochemistry on NRCM transduced with AdDMPK E with 
or without lenti-SRF-TASA. D. Quantification of the myofibrillar structure in NRCM transduced 
with AdDMPK E with our without SRF-TASA, showing improvement of the sarcomere structure 
upon SRF-TASA expression. AdDMPK E: n=102 cells, AdDMPK E/SRF-TASA: n=53 cells, from 
3 independent isolations. ***P<0.001 versus AdDMPK E, one way ANOVA followed by Tukey’s 
post-test. Scale bar = 20 μm. 
 
Figure 7. Cardiac specific overexpression of DMPK E induces loss of sarcomeric 
structure and cardiomyopathy. 
A. Western blot for DMPK on cardiac lysates from mice from two independent DMPK E and two 
DMPK E (K100A) transgenic lines. Note the absence of DMPK autophosphorylation product 
(higher protein band) in DMPK E (K100A) mice. B. QPCR analysis showing DMPK E mRNA 
expression in WT (n=10), DMPK E lines 1 (n=3) and 2 (n=4), and in DMPK E (K100A) lines 1 
(n=3) and 2 (n=5) hearts. *** P<0.001 versus all transgenic lines, P<0.05, ## P<0.01 vs DMPK E 
line 1, one way ANOVA followed by Tukey’s post-test.  C. Kaplan-Meier curve revealing 
increased mortality in DMPK E compared to WT and DMPK E (K100A) transgenic mice. WT: 
n=38, DMPK E line 1: n=29, DMPK E line 2: n=27, DMPK E (K100A) line 1: n=26, DMPK E 
(K100A) line 2: n=24 . D. Representative images of whole hearts and H&E stained sections from 
8 months old WT and transgenic mice and a 5 months old DMPK E line 1 transgenic mouse, 
displaying cardiomyopathy after overexpression of DMPK E, but not DMPK E (K100A). E, F. Dot 
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plots indicating an increase in heart weight-to-tibia length (HW/TL) (E) and lung weight-to-tibia 
length (LuW/TL) (F) in DMPK E transgenic mice (line 1: 4-5 months old, n=6; line 2: 8-10 months 
old, n=8) compared to 8-10 months old WT (n=8) and DMPK E (K100A) transgenic mice (line 1: 
n=10; line 2: n=6).  *P<0.05, **P<0.01, ***P<0.001 vs WT; #P<0.05, ##P<0.01, ###P<0.001 vs 
DMPK E line 1; $P<0.05 vs DMPK E line 2, one way ANOVA followed by Tukey’s post-test. G. 
Electron microscopy images of hearts of 10 week old WT, DMPK E and DMPK E (K100A) mice 
displaying heavily disorganized sarcomeres in DMPK E hearts. Scale bar = 5 μm. H. 
Quantification of EM sarcomere structure score. WT (n=155 EM pictures), DMPK E line 1 
(n=155 EM pictures), DMPK E (K100A) line 1 (n=102 EM pictures) from 3 to 4 mice per group. 
***P<0.001 vs WT, ###P<0.001 vs DMPK E, one way ANOVA followed by Tukey’s post-test. I. 
Confocal images of cardiac sections from 10 week old mice, stained for α-actinin (green), SRF 
(red) and DAPI (blue), demonstrating a loss of sarcomere organization in DMPK E transgenic 
hearts. Scale bar = 20 μm. J. Quantification of cardiomyocytes with SRF positive nuclei, showing 
a decrease in number of SRF positive cardiomyocytes in DMPK E transgenic mice compared to 
WT and DMPK E (K100A) transgenic controls (10 weeks old, n=4 for all groups). ***P<0.001 vs 
WT, ###P<0.001 vs DMPK E, one way ANOVA followed by Tukey’s post-test. K. QPCR analysis 
of SRF-regulated sarcomeric genes in WT (Ttn: n=4, Actn2: n=4, Myl2: n=4, Acta1: n= 5), DMPK 
E (Ttn: n=5, Actn2: n=4, Myl2: n=6, Acta1: n=4) and DMPK E (K100A) (Ttn: n=3, Actn2: n=3, 
Myl2: n=4, Acta1: n=4) transgenic mice. *P<0.05, **P<0.01, ***P<0.001 vs WT; #P<0.05, 
##P<0.01, ###P<0.001 vs DMPK E, one way ANOVA followed by Tukey’s post-test. 
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
Downloaded from https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy091/4965938
by Edinburgh University user
on 13 April 2018
